The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics

Siccardi, Marco ORCID: 0000-0002-3539-7867, Schapiro, Jonathan, Di Perri, Giovanni and Back, David J
(2020) The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75 (9). pp. 2381-2383.

[img] Text
dkaa272 (1).pdf - Published version

Download (125kB) | Preview


The development of therapeutic agents against SARS-CoV-2/COVID-19  faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings.

Item Type: Article
Uncontrolled Keywords: Animals, Humans, Pneumonia, Viral, Coronavirus Infections, Antibodies, Viral, Antiviral Agents, Drug Discovery, Pandemics, Betacoronavirus, COVID-19, SARS-CoV-2
Depositing User: Symplectic Admin
Date Deposited: 06 Jul 2020 09:59
Last Modified: 18 Jan 2023 23:47
DOI: 10.1093/jac/dkaa272
Related URLs: